Stonehaven Incubate celebrates first birthday with new friends
27th March, 2019
Stonehaven Incubate is celebrating its first birthday and already has three active on-going collaborations to drive improvements in animal health.
“We have evaluated over 33 opportunities in the past 12 months, we’ve actively moved forward on three and we have a number in negotiation, with memorandums of understanding and option agreements underway. We target at least three opportunities a year, but may take in up to five,” said Dr Mark Heffernan, CEO of Stonehaven Incubate. “There is no shortage of fantastic science and technology out there on the human side and what Stonehaven Incubate is all about is taking that cutting edge technology and moving it across to animal health.”
In line with its annual targets, Stonehaven Incubate is now working with Anizome, a company focused in the area of microbiome, Lysando, which is developing antimicrobial peptides, and most recently announced its agreement with Agile Sciences, which is adjuventing antibiotics.
Notes to editor:
Swiss based Stonehaven Incubate was formed in February 2018 and is a dedicated, animal health group committed to creating new companies de novo from disruptive human technology. Stonehaven Incubate works with innovators and builds strategies for new, stand-alone animal health companies. It finds experienced management teams and sources the required capital, leaving no stone unturned in its quest to bring human innovations to animal health.
Its parent company, Stonehaven Holdings AG, was founded in 2015 by George Gunn, former CEO of Novartis AH.
ANIZOME LLC was founded in 2018 as a result of a ground-breaking venture between Baylor College of Medicine, Stonehaven Incubate AG and Diversigen Inc. This unique combination of microbiome expertise, industry knowledge and commercial experience has enabled ANIZOME to establish a world-class animal microbiome platform that bridges the gap between research and commercial solutions.
Located in the Texas Medical Centre, the world’s largest health science complex, ANIZOME’s experienced team of experts are building on more than a decade of breakthrough discovery in the microbiome to develop next generation solutions for both farm and companion animals.
Founded in 2009 by Markus Count Matuschka von Greiffenclau. Lysando AG with its German subsidiary Lisando GmbH located at the Biopark, Regensburg has a team of 20 top scientists developing Artilysin®. This globally unique technology enables the development of anti-microbial proteins which are highly resistant-stable and save the natural microbiome. To date 450 functional Artilysin®s have been developed. It is the company’s goal to turn the Artilysin® platform into the world leading anti-microbial technology.
Agile Sciences, Inc.
Agile Sciences, Inc. is a pre-clinical stage biopharmaceutical company based in Raleigh, NC USA. It is pioneering an entirely new mechanistic approach for the treatment of antibiotic resistant, life-threatening infections.
It was founded in 2007 by Dr. John Cavanagh, previously at the Department of Molecular & Structural Biochemistry at North Carolina State University (NCSU) and Dr. Christian Melander, George & Winifred Clark Professor, Department of Chemistry and Biochemistry Notre Dame University.
To date, Agile Sciences has received over $12M USD in grants and contracts from the US government and private foundations. Its three main areas of focus are:
- Multi-drug resistant gram-negative pathogens
- Dispersion and inhibition of biofilms in Cystic Fibrosis patients
- Chronic wound healing
For more information contact Mike Keeler or Alistair Moses at Garnett Keeler PR on +44 (0)20 8647 4467 or /